CA3091458A1 - Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto - Google Patents

Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto Download PDF

Info

Publication number
CA3091458A1
CA3091458A1 CA3091458A CA3091458A CA3091458A1 CA 3091458 A1 CA3091458 A1 CA 3091458A1 CA 3091458 A CA3091458 A CA 3091458A CA 3091458 A CA3091458 A CA 3091458A CA 3091458 A1 CA3091458 A1 CA 3091458A1
Authority
CA
Canada
Prior art keywords
functionalized cyclodextrin
functionalized
cyclodextrin
nitric oxide
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3091458A
Other languages
English (en)
French (fr)
Inventor
Mark H. Schoenfisch
Haibao JIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of CA3091458A1 publication Critical patent/CA3091458A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
CA3091458A 2018-03-06 2019-03-06 Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto Pending CA3091458A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862639119P 2018-03-06 2018-03-06
US62/639,119 2018-03-06
PCT/US2019/021051 WO2019173539A1 (en) 2018-03-06 2019-03-06 Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto

Publications (1)

Publication Number Publication Date
CA3091458A1 true CA3091458A1 (en) 2019-09-12

Family

ID=67847502

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3091458A Pending CA3091458A1 (en) 2018-03-06 2019-03-06 Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto

Country Status (7)

Country Link
US (2) US11026965B2 (https=)
EP (1) EP3762039A4 (https=)
JP (1) JP7565588B2 (https=)
CN (1) CN111836648A (https=)
AU (1) AU2019231712B2 (https=)
CA (1) CA3091458A1 (https=)
WO (1) WO2019173539A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018067838A1 (en) 2016-10-07 2018-04-12 The University Of North Carolina At Chapel Hill S-nitrosothiol-mediated hyperbranched polyesters
WO2018127819A1 (en) 2017-01-03 2018-07-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
JP7403152B2 (ja) 2017-03-28 2023-12-22 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 生分解可能な抗菌性スキャフォールドとしての一酸化窒素放出性ポリアミノグリコシドおよびそれに関する方法背景
EP3710514B1 (en) 2017-11-15 2023-06-07 The University of North Carolina at Chapel Hill Nitric oxide-releasing hyperbranched compounds as antibacterial scaffolds and methods pertaining thereto
CA3091458A1 (en) 2018-03-06 2019-09-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
CN113383019B (zh) 2018-12-28 2023-11-17 北卡罗来纳大学教堂山分校 一氧化氮释放型抗菌聚合物和由其制成的支架和其相关方法
EP4093205A4 (en) * 2020-02-07 2024-02-21 KNOW Bio, LLC Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto
CN111155177B (zh) * 2020-02-11 2022-03-22 福建师范大学 静电纺丝抗病毒薄层及其在抗病毒领域的应用
GB202007928D0 (en) * 2020-05-27 2020-07-08 Attgeno Ab New uses and methods
WO2022132748A1 (en) * 2020-12-14 2022-06-23 Bps Just Energy Technology, Llc Antimicrobial compositions with supramolecular structures
CN112946160B (zh) * 2021-02-09 2022-10-25 新疆大学 一种活性物质贡献率的计算方法、系统、设备及其存储介质
CN113396964A (zh) * 2021-05-27 2021-09-17 浙江工商大学 由没食子酸辛酯与内生no型环糊精介导的高效保鲜纳米纺丝膜及其制备方法和应用
CN113975288A (zh) * 2021-10-28 2022-01-28 中国药科大学 α、β或γ环糊精在制备治疗溃疡性结肠炎药物中的应用
WO2023239551A1 (en) * 2022-06-08 2023-12-14 Virginia Commnwealth University Guest/host inclusion complexes containing s-nitrosoglutathione and methods of use thereof
CN115340615B (zh) * 2022-08-12 2023-05-02 同济大学 一种基于环糊精-氨基酸的荧光分子及其合成方法与应用
CN116425644B (zh) * 2023-03-09 2026-04-14 西北大学 一种水溶光诱导释放一氧化氮抗菌的超分子复合物及其制备和应用
CN116574202B (zh) * 2023-04-12 2024-05-10 华南理工大学 一种含海因结构的壳聚糖双季铵盐抗菌剂及其制备方法与应用

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169079A (en) * 1977-10-24 1979-09-25 Iwao Tabushi Polystyrene based polymers containing cyclodextrin derivatives, metal complexes of the same, and process for the production of the same
US5574027A (en) 1989-11-22 1996-11-12 Bernstein; Lawrence R. Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones
US5234933A (en) 1991-10-31 1993-08-10 Board Of Governors Of Wayne State University And Vanderbilt University Cyclic hydroxamic acids
DE4210332C1 (https=) 1992-03-30 1993-07-15 Gruenenthal Gmbh, 5100 Aachen, De
US5814666A (en) 1992-04-13 1998-09-29 The United States As Represented By The Department Of Health And Human Services Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
US5238832A (en) 1992-06-08 1993-08-24 Board Of Governors Of Wayne State University Aryl aliphatic acids
US5525357A (en) 1992-08-24 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US6200558B1 (en) 1993-09-14 2001-03-13 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US5650447A (en) 1992-08-24 1997-07-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitric oxide-releasing polymers to treat restenosis and related disorders
US5405919A (en) 1992-08-24 1995-04-11 The United States Of America As Represented By The Secretary Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders
US5632981A (en) 1992-08-24 1997-05-27 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US5910316A (en) 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US5691423A (en) * 1992-08-24 1997-11-25 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-bound nitric oxide-nucleophile adducts
AU685178B2 (en) 1993-10-08 1998-01-15 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers
US5840759A (en) 1993-10-08 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents
ATE192922T1 (de) 1993-11-02 2000-06-15 Us Health Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden
CA2205564C (en) 1994-11-22 2006-07-11 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions comprising nitric oxide-releasing biopolymers
US5714511A (en) 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US6232434B1 (en) * 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5770645A (en) * 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US20030093143A1 (en) 1999-03-01 2003-05-15 Yiju Zhao Medical device having surface depressions containing nitric oxide releasing compound
JP4285775B2 (ja) 1996-09-27 2009-06-24 アメリカ合衆国 Ｏ▲上２▼―アリール化またはｏ▲上２▼―グリコシル化１―置換ジアゼン―１―イウム―１，２―ジオレート類およびｏ▲上２▼―置換１―［（２―カルボキシラト）ピロリジン―１―イル］ジアゼン―１―イウム―１，２―ジオレート類
EP2292630B1 (en) * 1996-09-27 2015-11-25 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services O2-substituted 1- (2-carboxylato)pyrrolidin-1-yl diazen-1-ium-1,2-diolates
NO305033B1 (no) 1997-05-09 1999-03-22 Algipharma As Fremgangsmate for fremstilling av uronsyreblokker fra alginat
US6180082B1 (en) 1997-11-24 2001-01-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method to enhance tissue accumulation of radiolabeled compounds
US6207855B1 (en) 1998-06-23 2001-03-27 Duke University Medical Center Stable no-delivering compounds
US6261594B1 (en) 1998-11-25 2001-07-17 The University Of Akron Chitosan-based nitric oxide donor compositions
JP4870314B2 (ja) 2000-05-02 2012-02-08 セラヴァンス， インコーポレーテッド シクロデキストリンを含むグリコペプチド抗生物質組成物
JP2002179647A (ja) 2000-12-11 2002-06-26 Kikkoman Corp ニコチアナミン又はニコチアナミン含有物の製造法
AUPR879601A0 (en) 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
DE60302454T2 (de) 2002-04-19 2006-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonisten-verbindungen mit stickoxid-donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
NO335366B1 (no) 2002-07-26 2014-12-01 Algipharma As Mutantstamme Pf201 av Pseudomonas fluorescens og anvendelse derav i alginatproduksjon,samt fremgangsmåte for fremstilling derav.
NO20023581D0 (no) 2002-07-26 2002-07-26 Fmc Biopolymer As Nye mutantstammer av Pseudomonas fluorescens og varianter derav, metoder for produksjon og bruk derav til produksjon avalginat
BRPI0314042B8 (pt) 2002-09-06 2021-05-25 Calando Pharmaceuticals Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
US20050009789A1 (en) 2003-05-13 2005-01-13 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Service Cyclooxygenase inhibition with nitroxyl
JP2005047979A (ja) 2003-07-30 2005-02-24 Dainippon Ink & Chem Inc 多分岐ポリマーの製造方法、及び多分岐ポリマー
SG113562A1 (en) 2004-01-12 2005-08-29 Agency Science Tech & Res Polyalkyleneimine-graft-biodegradable polymers for delivery of bioactive agents
CN101151037A (zh) * 2005-01-28 2008-03-26 平纳克尔医药股份有限公司 作为抗菌剂的β-环糊精衍生物
ES2731298T3 (es) 2005-05-27 2019-11-14 Univ North Carolina Chapel Hill Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas
GB0515550D0 (en) 2005-07-29 2005-09-07 Univ Strathclyde Inactivation of staphylococcus species
WO2007053292A2 (en) 2005-10-31 2007-05-10 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates
JP2009523584A (ja) 2006-01-24 2009-06-25 ミリメッド・アクティーゼルスカブ Ｐｈ依存性薬物放出を有する医療デバイス
US7854923B2 (en) 2006-04-18 2010-12-21 Endomedix, Inc. Biopolymer system for tissue sealing
GB0707096D0 (en) 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
CN101049513B (zh) 2007-05-13 2010-05-19 刘万顺 水溶性壳聚糖基纤维止血愈创材料及其制备方法和应用
ITMI20071341A1 (it) 2007-07-05 2009-01-06 Fidia Farmaceutici Derivati di acido ialuronico contenenti gruppi in grado di rilasciare no
US8273828B2 (en) * 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
EP2209472A1 (en) 2007-10-12 2010-07-28 The University of North Carolina at Chapel Hill Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents
HUE034051T2 (en) 2007-11-27 2018-01-29 Algipharma As Use of alginate-containing oligomers to combat biofilms
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
US20090232863A1 (en) 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
EP2260060A4 (en) 2008-04-01 2013-01-16 Univ Cornell ORGANIC SOLUBLE CHITOSA SALT AND CHITOSAN DERIVED BIOMATERIALS MANUFACTURED THEREFROM
CN102256989B (zh) 2008-10-03 2016-01-06 聚糖生物科学有限责任公司 糖基化细菌代谢物的阴离子轭合物
EP2398761A4 (en) 2009-02-18 2015-11-04 Bezwada Biomedical Llc CONTROLLED RELEASE OF NITRIC OXIDE AND MEDICINES FROM FUNCTIONALIZED MACROMERS AND OLIGOMERS
GB0904941D0 (en) 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
US20120107229A1 (en) 2009-04-15 2012-05-03 Xuefei Huang Novel nano-probes for molecular imaging and targeted therapy of diseases
US9539233B2 (en) 2009-05-04 2017-01-10 Aridis Pharmaceuticals Inc. Gallium formulation for the treatment and prevention of infectious diseases
ES2444541T3 (es) 2009-06-03 2014-02-25 Algipharma As Oligómeros de alginato para usar para superar la multirresistencia a fármacos en bacterias
GB0909529D0 (en) 2009-06-03 2009-07-15 Algipharma Ipr As Alginate oligomers for the inhibition of microbial adherence to surfaces
GB0909557D0 (en) 2009-06-03 2009-07-15 Algipharma Ipr As Anti-microbial alginate oligomers
US9957341B2 (en) 2009-06-09 2018-05-01 William Chambers Biodegradable absorbent material and method of manufacture
CA2671595A1 (en) 2009-07-09 2011-01-09 Ping I. Lee Controlled nitric oxide delivery from aqueous s-nitrosothiol conjugated polymers and their complexes
US8551456B2 (en) 2010-03-05 2013-10-08 University Of Dayton Combination therapy and methods for treating bacterial biofilms
EP2547660B1 (en) 2010-03-19 2015-01-07 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Nitroxyl (hno) releasing compounds and uses thereof in treating diseases
KR101272351B1 (ko) 2010-04-23 2013-06-07 이화여자대학교 산학협력단 새로운 카나마이신 화합물, 카나마이신 생산 스트렙토마이세스 속 미생물 및 카나마이신의 생산 방법
KR101255337B1 (ko) 2010-10-04 2013-04-16 한국과학기술연구원 온도 감응성 합성 고분자를 이용한 일산화질소 전달체
US9034355B2 (en) 2011-02-24 2015-05-19 Colorado State University Research Foundation Materials for modulating biological responses and methods of making
WO2013029009A1 (en) * 2011-08-24 2013-02-28 Novan, Inc. Tunable nitric oxide-releasing macromolecules having multiple nitric oxide donor structures
GB201116010D0 (en) 2011-09-15 2011-10-26 Algipharma As Use of alginate oligomers to enhance the effects of antifungal agents
US9017653B2 (en) 2012-06-14 2015-04-28 The Board Of Regents Of The University Of Texas System Nitric oxide-releasing compositions and methods
CN106986952B (zh) 2012-08-17 2020-03-10 北卡罗来纳大学查珀尔希尔分校 水溶性的释放一氧化氮的聚葡糖胺和其用途
WO2014138425A1 (en) 2013-03-08 2014-09-12 Allergan, Inc. Cyclosporine a-steroid conjugates
GB201322777D0 (en) 2013-12-20 2014-02-05 Algipharma As Use of alginate oligomers as blood anticoagulants
JP2017501221A (ja) 2013-12-23 2017-01-12 ノルウェージャン ユニバーシティ オブ サイエンス アンド テクノロジー（エヌティーエヌユー） がん治療におけるオリゴウロン酸塩の使用
RU2016136449A (ru) 2014-02-28 2018-04-02 АльгиФарма АС Применение олигометов альгината в лечении муковисцидоза и других состояний, ассоциированных с нарушенной функцией ионных каналов cftr
GB201415381D0 (en) 2014-08-29 2014-10-15 Algipharma As Inhalable powder formulations of alginate oligomers
WO2016073835A1 (en) 2014-11-06 2016-05-12 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods of diazeniumdiolate-based prodrugs for treating cancer
GB201504878D0 (en) 2015-03-23 2015-05-06 Algipharma As Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
US11170451B2 (en) 2015-10-02 2021-11-09 Not So Forgetful, LLC Apparatus and method for providing gift recommendations and social engagement reminders, storing personal information, and facilitating gift and social engagement recommendations for calendar-based social engagements through an interconnected social network
GB201517639D0 (en) 2015-10-06 2015-11-18 Algipharma As Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
CN106046382B (zh) 2016-05-25 2018-10-09 暨南大学 一种装载一氧化氮的阳离子聚合物及其制备方法和应用
WO2018067838A1 (en) 2016-10-07 2018-04-12 The University Of North Carolina At Chapel Hill S-nitrosothiol-mediated hyperbranched polyesters
WO2018127819A1 (en) 2017-01-03 2018-07-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
JP7403152B2 (ja) 2017-03-28 2023-12-22 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 生分解可能な抗菌性スキャフォールドとしての一酸化窒素放出性ポリアミノグリコシドおよびそれに関する方法背景
EP3710514B1 (en) 2017-11-15 2023-06-07 The University of North Carolina at Chapel Hill Nitric oxide-releasing hyperbranched compounds as antibacterial scaffolds and methods pertaining thereto
CA3091458A1 (en) 2018-03-06 2019-09-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
US11102301B2 (en) 2018-07-12 2021-08-24 Sap Se PCA-based scoring of the similarity of damage patterns of operational assets
CN113383019B (zh) 2018-12-28 2023-11-17 北卡罗来纳大学教堂山分校 一氧化氮释放型抗菌聚合物和由其制成的支架和其相关方法

Also Published As

Publication number Publication date
US11026965B2 (en) 2021-06-08
JP7565588B2 (ja) 2024-10-11
EP3762039A1 (en) 2021-01-13
US11672818B2 (en) 2023-06-13
US20210346424A1 (en) 2021-11-11
AU2019231712B2 (en) 2025-04-10
EP3762039A4 (en) 2021-12-22
WO2019173539A1 (en) 2019-09-12
CN111836648A (zh) 2020-10-27
AU2019231712A1 (en) 2020-10-15
JP2021515083A (ja) 2021-06-17
US20190343869A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
US11672818B2 (en) Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
US11697693B2 (en) Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
EP3710514B1 (en) Nitric oxide-releasing hyperbranched compounds as antibacterial scaffolds and methods pertaining thereto
US20040072798A1 (en) Compositions comprising cyclodextrins and no-releasing drugs
US11723914B2 (en) Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto
EP3902841B1 (en) Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto
JP2022516032A (ja) 抗体－薬物複合体
EP3218010B1 (en) Polymer composed of repeat units having a biologically active molecule attached thereto via a ph-sensitive bond

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240305

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250221

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250221

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250221

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250321

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250721

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250724

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250804

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250804

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260212